chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19 infection; COVID-19 infection; This is a spontaneous report received from a contactable reporter(s) (Consumer), Program ID: (174529). The reporter is the parent.  An 8-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19 infection". It was reported that the patient was diagnosed with COVID-19 infection after being fully vaccinated with the Pfizer COVID-19 vaccine.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Moderna COVID-19 Vaccine EUA    (1 hour after injection - sore arm) (17 hours after injection - very achy, very tired, headache, loss of appetite, weak) Took ibuprofen 600mg / 800 mg (22 hours after injection - fever plus above, sweating, weak) (46 hours after injection - symptoms cleared quickly except ache and hardness at injection site and ache in mid-back) Took ibuprofen 600 mg
presented with dizziness, headache, eye pain. Patient was diagnosed with fever, headache, and acute conjunctivitis.; presented with dizziness, headache, eye pain. Patient was diagnosed with fever, headache, and acute conjunctivitis.; presented with dizziness, headache, eye pain. Patient was diagnosed with fever, headache, and acute conjunctivitis.; presented with dizziness, headache, eye pain. Patient was diagnosed with fever, headache, and acute conjunctivitis.; Information has been received from a medical assistant, referring to a 12 year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.   On 19-MAY-2023, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection administered for prophylaxis (lot #, expiration date, strength, administration route and anatomical location was not provided).  Later, on 21-JUN-2023, the patient received the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 0.5 milliliter, lot #W027455, expiration date: 04-JAN-2025, administered intramuscularly for prophylaxis (strength was not provided).  On 22-JUN-2023, the patient was seen by a physician and presented with dizziness, headache, eye pain. Then, the patient was diagnosed with fever, headache, and acute conjunctivitis (onset of the events was June 2023).  At the time of reporting, the outcome of all the events presented was unknown and the causal relationship between dizziness, headache, eye pain, fever and acute conjunctivitis was not provided.
One month after the second dose of Moderna, meat began tasting rotten. It steadily became worse where nearly all meat, corn, and onions taste and smell extremely rotten. Chicken and ham occasionally taste bad. I have seen my primary care physician who ran blood work to rule out vitamin D deficiency. I am now seeing an ENT who has prescribed three different nose sprays, plus a round of prednisone. Nose sprays are - saline spray (over the counter), XHance, and Azelastine. I finished the prednisone and am still using the nose sprays (one week now).
Tested positive for covid on Friday 10Sep; Tested positive for covid on Friday 10Sep; 12-13 days after the vaccine the caller felt sick; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received bnt162b2 (BNT162B2, Solution for injection, Batch/Lot number was not reported)  via an unspecified route of administration on 27Aug2021 as dose 1, single for COVID-19 immunisation. The patient medical history  and concomitant medications were not reported. It was reported that the patient received her first dose of the Pfizer covid vaccine on 27Aug and 12-13 days after the vaccine the patient felt sick and tested positive for covid on Friday 10Sep. The caller has stated that she can't find anything online to support her argument about the 10-13 days and she doesn't want to sound like an idiot while trying to support something or someone and also she wanted to know when someone gets their first COVID shot how long afterwards can they expect to experience possible side effects, could it be 10-13 days and then the patient has tested positive for COVID. The patient stated that she wanted to know if its normal to still be feeling the side effects of the vaccine after this long. Outcome of the events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Sneezing attacks; Congestion (could not breathe out of my nose); This is a spontaneous report from a contactable healthcare professional. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 03Apr2021 at 16:15 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included atomoxetine hydrochloride (STRATTERA) from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 21:00, the patient experienced sneezing attacks and congestion (could not breathe out of her nose). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sneezing attacks and congestion (could not breathe out of her nose) was recovered on 04Apr2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
5cm area of fine skin-colored papules on left thigh around immunization site. Mom reports this also happened with his 2 month vaccines.
Developed rash on scalp, chest arms, legs. Small ovoid 0.5-1 cm well defined scaling lesions in a patchy distribution.
elevated heart rate. My heart rate went from high 70s to low 80 to low 100s. It stayed at that level for 12 hours before falling below 100 into the 90s. The next morning it was back to its regular rate.
42 days have passed since 1st shot for a patient; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (42 days have passed since 1st shot for a patient) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (42 days have passed since 1st shot for a patient). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (42 days have passed since 1st shot for a patient) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.
Achy arms; Aches all over; Her shoulders hurts; Injection site itches; Fatigue; A spontaneous report was received from a consumer concerning a 77 years old patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events aches all over, her shoulders hurts, injection site itches, fatigue, achy arms.  The patient's medical history provided was cancer in her ovaries and stent in place. No relevant concomitant medications were reported.  On 22 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: Unknown) intramuscularly at unknown anatomical location for prophylaxis of COVID-19 infection.  on an unknown date, the patient developed aches all over, her shoulders hurts, injection site itches, fatigue, achy arms.  Treatment details included Acetaminophen  Action taken with mRNA-1273 in response to the events was not reported.   On an unknown date the outcome of events, aches all over, her shoulders hurts, injection site itches, fatigue, achy arms was not reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
A report has been received from a Physician concerning a, female subject, who had been receiving FLUMIST, 0.2 millilitres, unknown. FLUMIST started on an unknown date. The patient experienced fever of 103-104 temperature. FLUMIST was continued. The outcome of the event of fever of 103-104 temperature was unknown. The report was considered to be non-serious.
Administered Moderna vaccination at 12:40 pm Sunday April  11,2021. Instructed patient to sit and wait in the vaccination waiting area for 15 minutes. Patient approached me  10 minutes into waiting time and told me he did not feel well. Patient was drenched in sweat. I instructed my tech to paged code white while I stayed with him. I advised him to remove his sweater and face mask. He said he had labored breathing and did not have much energy to talk. I provided him with ice pack, and had him sit down in the clinical service room. His sweat was dissipating. His finance stated he may need electrolytes and he gets anxious with needles. Front lead staff provided him with Gatorade, he took few sips.  He requested Emergency medical services to be called. He called his finance on the phone and informed her of his current condition. He stated he drove 1 hour and 45 minutes to get here and did not feel well enough to drive. EMS came on site and evaluated him. The patient requested to be taken to hospital, after further evaluation they transported him to the hospital. Patient was alert, but seemed slow to respond to questions. He kept stating he did not feel well. We advised him we call EMS and they are on the way.
About 4-5 days after my vaccine, I woke up with excruciating burning pain under my skin in my knee that felt like my leg was on fire. It lessened, but a faint pain remained and came and went for the following 24 hours. It went away for about a week, then came back. It is no longer excruciating pain like the first event which I haven?t felt since then, but it comes as a small burning sensation that occurs at random times at completely random parts of my body. It feels almost like a precise, burning nerve pain, but not pins and needles. I have felt it nearly everywhere on my body from literally my head to my toes, and almost everywhere in between. It lasts for no longer than a minute, and it only shows up in one or two areas of my body at once. It comes and goes often, so some days it?s constant and appears nearly all day, but some days I don?t feel it at all or only a small amount.
Ankle pain, joint immobility, swelling, on crutches  7 days and counting
Information regarding Flumist was received from a company representative regarding a female pt (who is the nurse) who experienced teary eyes, scratchy throat and bronchial spasms. Thhe pt, is also the nurse, who sprayed the Flumist into the air. She experienced teary eyes, scratchy throat and bronchial spasms. A bronchial neublizer treatment was administered and she recovered. The reporter indicated that ten other people were in the room and "they are all fine." No additional info was available at the time of this report.
Varicella vaccine breakthrough. Diagnosed with varicella on 9-29-07. Had 7 vesicles. Low-grade temp-tactile. 1 vesicle was infected - impetigo - treated with Bactrim.
Received vaccine above had fever at 9pm, received Tylenol PO. Started rolling of eye balls, no seizures temp 102 deg F. Seen in ER, discharged home. No symptoms.
sore arm; This is a spontaneous report from a contactable consumer (patient). A 34-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: P220895-0068L), via an unspecified route of administration, in left arm on 02Feb2021 at 15:45 (at the age of 34-year-old) as 1st dose, single dose for covid-19 immunisation. Medical history included allergy to penicillin. Concomitant medications that patient received within 2 weeks of vaccination included naproxen (NAPROXEN) and levonorgestrel (KYLEENA). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not prior to vaccination and was not diagnosed with COVID-19. On 03Feb2021 at 07:00, the patient experienced sore arm. The patient did not receive treatment for the adverse event. Since the vaccination, the patient was not tested for COVID-19. The report was non-serious. Outcome of the event was recovered on an unknown date.  Follow-up attempts are completed. No further information is expected.
On January 5, 2022, it started with severe migraines at nighttime in bed. When I woke up the next day I woke up with muscle aches and feeling really crappy. I tested myself on January 6, 2022, with my at home test and I tested positive. I contacted my doctor on Thursday or Friday that same week, to let them know that I tested positive for COVID-19. My doctor sent me a inhaler just in case I needed it. On January 17, 2022, I tested negative for COVID-19.
Patient was sitting on dad's lab in waiting area after vaccine. After about 5 minutes following vaccine, she leaned forward when faiting, hitting her head on the floor.  She came to quickly and had a cut on her hairline which was cleaned/treated.  She was observed for 20 minutes by staff and was not having any complications.
Information has been received from a physician concerning an 80 year old female patient with no allergies and a history of shingles on her right buttocks and thigh on 07-FEB-2007 who on 03-JAN-2008 was vaccinated SC with a dose of zoster vaccine live (Oka/Merck). On 05-MAR-2008, the patient experienced occipital neuralgia and stabbing and lacerating pain on the left side of face. The patient has been prescribed NEURONTIN for the treatment. No diagnostic laboratory tests were performed. At the time of this report, the patient was recovering. No product quality complaints were involved. Further information has been requested.
tingling in the extremities; burning sensation; This is a spontaneous report from a contactable pharmacist. A 21-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration on an unspecified date as dose 2, single for COVID-19 immunisation.  The patient's medical history and concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) for COVID-19 Immunization and no reaction on previous exposure to vaccine. The patient was hospitalized after the second dose of the COVID-19 vaccine. The person has been two weeks in the hospital. Initial symptoms were tingling in the extremities that turned into burning sensation. Patient was much better with minimal, sporadic symptoms. The patient was hospitalized for the events for 14 days. The outcome of the event was recovered with sequel.   Information on lot/batch number has been requested.; Sender's Comments: Based on the temporal association, a possible contributory role of BNT162B2 to the development of tingling in the extremities and burning sensation cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
Pt. reported having pain, lump, pus, edema to site a few days after Tdap. Tdap given 12-5-11. Pt. reported this to me 12/19/11.  Lump, sloughing skin.
ankylosing spondylitis; This spontaneous report was received from a registered nurse via a Company representative and refers to the reporter's son, 17-year-old male patient. He has had autoimmune issues throughout his life. There was no information regarding his medical history nor concomitant therapies provided.  In approximately 2019, when he was 15 years old, the patient was vaccinated with a dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) 0.5 ml, intramuscularly (IM) (anatomical location, lot # and expiration date were not provided) for a routine inoculation. In approximately January 2021 (reported as about 4 months ago and recently), the patient was diagnosed with ankylosing spondylitis. He sought medical attention (details not provided). It was unknown whether he received any treatment for the event. The outcome of the event was unknown.  The reporter believed her son's diagnosis of ankylosing spondylitis was related to HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9).  Upon internal review, the event of ankylosing spondylitis was considered to be medically significant.
Lt arm tri-cep area red and inflammed, warm to touch. (+) rubor, color, deter 14x19cm. No definite induration or lymph, streaking. No papules. No constitutional symptoms. Began 1st day of vaccine and progressed. A/P: local rxn. Large, simple "LR 5" index, allegra, f/u with PCM.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 58-year-old female patient who received SHINGRIX for prophylaxis. On 11th September 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On 11th September 2018, immediately after receiving SHINGRIX, the patient experienced injection site pain and injection site discoloration. On 12th September 2018, the patient experienced influenza-like symptoms, pain and watering eyes. On 12th September 2018, the outcome of the injection site pain was recovered/resolved. On 13th September 2018, the outcome of the influenza-like symptoms, pain and watering eyes were recovered/resolved. On an unknown date, the outcome of the injection site discoloration was recovered/resolved. It was unknown if the reporter considered the injection site pain, influenza-like symptoms, pain, watering eyes and injection site discoloration to be related to SHINGRIX. Additional details were received as follows: As the patient received SHINGRIX vaccine, the vaccine hurted as it was being injected. By early evening the injection site on left arm was sore to the touch.   Later in the evening, the patient had fist size black and blue area as well as continued soreness at the injection site. On the next day, she felt fine early in the day. That afternoon, the patient was felt like she was getting the flu. The patient felt a little achy and her eyes were watery. By the next day these symptoms were resolved. It took almost two weeks for the black and blue area to resolve. The reporter consented to follow up. The reporter gave permission for her physician to be contacted. The reporter was unable to obtain additional information. For to tolerance, refer case US2018GSK226117.
Patient received Johnson&Johnson CV-19 1805018 5/21 on March 9, 2021.  Patient began experiencing chest pains and abnormal sensations in chest area beginning April 26, 2021.   Patient began experiencing electrical-like abnormalities in both hands and feet that cause severe dysfunction beginning May 7, 2021.  Patient developed blood clot behind the retina of right eye as examined by ophthalmologist during clinical visit on May 25, 2021 at 8:15am appointment.
swelling of the right arm pit, swollen lymph nodes of R arm and R breast.  Tender to touch and painful when R arm is down
Information has been received from a school nurse (registered nurse) concerning a 5 year old female who on 03-FEB-2010 was vaccinated with VARIVAX (Merck) (lot# not reported). On 21-AUG-2010 (10 days ago) the patient developed chickenpox. The nurse stated initially the child's physician was not certain if it was chickenpox but the mom getting shingles prompted him to say the child had chickenpox. Medical attention was sought by office visit. At the time of the report the patient had not recovered. It was reported the the pregnant mother of the child diagnosed with a mild case of shingles after the child developed chickenpox. Follow up information has been received from the registered nurse indicated that there was no "exposure to VARIVAX". Again there was no adverse reaction to the VARIVAX (Merck), none were given. Follow up information has been received from the registered nurse concerning the 4 year old (previously reported as 5 year old) female patient who on 03-FEB-2010 was vaccinated with a dose of VARIVAX (Merck) (lot number unavailable). In August 2010 the patient developed chickenpox. On an unspecified date the patient recovered. This is one of several reports received from the same source. Additional information is not expected.
Infections; Patient is having a fit; Patient is having nervous breakdown; A Spontaneous  report  was received from a consumer concerning a 68-year-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced fit/seizure, nervous breakdown/mental disorder and infection.  The patient's medical history was provided as "allergic to all things". No concomitant medications were reported.   On 26 Feb 2021, approximately 11 days  prior to the onset of the events, the patient received the first of two planned doses of mRNA-1273 (Lot number: unknown) intramuscularly in an unknown location for prophylaxis of COVID-19 infection.   On 09 Mar 2021,patient developed fit and nervous breakdown for three days. After three days ,On 12 Mar 2021,patient was admitted in emergency room and was diagnosed with infection. Also the reporter inquired if it is safe to go for the second dose.  The event fit /seizure was considered as important medical event term.  The treatment medication was reported as antibiotics.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events patient developed fit and nervous breakdown was considered as resolved on 12 Mar 2021.The outcome of the event infection was considered as unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
In the evening after vaccination - pain at the injection site, weakness, mild headache, slight tingling in the heart. The day after vaccination - A feeling of tightness in the heart, tingling, uneven heart work, aching muscles and joints. The second day after vaccination - A feeling of constriction in the heart, tingling, uneven heart work, numbness of the left, lower leg. Cardiac side effects began to subside by the fifth day after vaccination, but recurrent tingling sensations in the heart and numbness in the left leg persisted for two weeks.